Pathologists supported by a new artificial intelligence tool outperformed Standard of Care/Gold standard in determining ...

And, although most of the studies indicate advantages for HER2 testing in a reference laboratory, if appropriate quality control procedures are in place, either IHC or FISH methods may be carried ...

The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, as well as a desire for more sensitive assays that may better quantify ...

Breast cancer classed as HER2-positive - defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease. However ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

HER2 negative breast cancer (measured as HER2 score of IHC 0, IHC 1+ or IHC 2+/ISH-).2 Endocrine therapies are widely given consecutively in the early lines of treatment for HR positive metastatic ...

A new study has demonstrated the value of Lunit’s AI-powered pathology tools in improving human epidermal growth factor receptor 2 (HER2) biomarker evaluation in metastatic colorectal cancer ...